Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man.
To determine whether the effects of platelet activating factor on the airways may be due to the production of leukotrienes we studied the effects of pretreatment with the selective cysteinyl leukotriene antagonist SK&F 104353-Z2 on the airway and cellular responses to inhaled platelet activating factor. Eight healthy men were studied in a randomised, double blind placebo controlled cross-over study. A single dose of platelet activating factor that caused a fall of at least 35% in specific airways conductance (sGaw) was determined initially for each subject. Challenge with this dose of platelet activating factor was then carried out on two further occasions after pretreatment with a single nebulised dose of SK&F 104353-Z2 or placebo. The % reductions in specific airways conductance and of partial flow at 30% of vital capacity (PVmax30) were less after SK&F 104353-Z2 than after placebo (22 versus 34 for sGaw, 19 versus 31 for PVmax30). The mean (95% confidence limits (CL] differences in the maximum % fall from control values for SK&F 104353-Z2 and placebo were -12.6 (-23.8, -1.4) for sGaw and -12.5, (-20.8 -4.2) for PVmax30. The mean % fall in neutrophil count was similar after SK&F 104353-Z2 (46%) and after placebo (50%) (95% CL of difference 13.6, 6.6). Bronchial responsiveness to methacholine did not increase above baseline values in any subject when measured two weeks after challenge by platelet activating factor. This study suggests that leukotrienes play a part in the response to platelet activating factor in man.
Spencer
D A
DA
Department of Thoracic Medicine King's College School of Medicine and Dentistry, London.
Evans
J M
JM
Green
S E
SE
Piper
P J
PJ
Costello
J F
JF
D000328:Adult; D001772:Blood Cell Count / Q000187:drug effects; D016084:Bronchoconstriction; D003998:Dicarboxylic Acids / Q000494:pharmacology*; D004311:Double-Blind Method; D005541:Forced Expiratory Volume; D006801:Humans; D015289:Leukotrienes / Q000502:physiology*; D008297:Male; D008688:Methacholine Compounds / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects; D010972:Platelet Activating Factor / Q000494:pharmacology*; D012119:Respiration / Q000187:drug effects; D013189:SRS-A / Q000037:antagonists & inhibitors*; D014797:Vital Capacity / Q000187:drug effects
D003998:Dicarboxylic Acids; D015289:Leukotrienes; D008688:Methacholine Compounds; D010972:Platelet Activating Factor; D013189:SRS-A; C052393:pobilukast